Early definitive treatment rate as a quality indicator of care in acute gallstone pancreatitis.
Published: 9th August 2017
Authors: R. Green, S. C. Charman, T. Palser
Early definitive treatment (cholecystectomy or endoscopic sphincterotomy in the same admission or within 2 weeks after discharge) of gallstone disease after a biliary attack of acute pancreatitis is standard of care. This study investigated whether compliance with early definitive treatment for acute gallstone pancreatitis can be used as a care quality indicator for the condition.
A retrospective cohort study was conducted using the Hospital Episode Statistics database. All emergency admissions to National Health Service hospitals in England with a first time diagnosis of acute gallstone pancreatitis in the financial years 2008, 2009 and 2010 were examined. Trends in early definitive treatment between hospital trusts were examined and patient morbidity outcomes were determined.
During the study interval there were 19 510 patients with an overall rate of early definitive treatment at 34·7 (range 9·4–84·7) per cent. In the 1‐year follow‐up period, 4661 patients (23·9 per cent) had one or more emergency readmissions for complications related to gallstone pancreatitis. Of these, 2692 (57·8 per cent) were readmissions for acute pancreatitis; 911 (33·8 per cent) were within the first 2 weeks of discharge, with the remaining 1781 (66·2 per cent) occurring after the point at which definitive treatment should have been received. Early definitive treatment resulted in a 39 per cent reduction in readmission risk (adjusted risk ratio (
In acute gallstone pancreatitis, compliance with recommended early definitive treatment varied considerably, with associated variation in outcomes. Compliance should be used as a quality indicator to improve care.Read more
You may also be interested in
Authors: T. Maeta, T. Ebata, E. Hayashi, T. Kawahara, S. Mizuno, N. Matsumoto et al.
Notes: Poor survival despite portal vein resection
Average treatment effect of hepatic resection versus locoregional therapies for hepatocellular carcinoma.
Authors: A. Cucchetti, V. Mazzaferro, A. D. Pinna, C. Sposito, R. Golfieri, C. Serra et al.
Notes: Resection is better
Meta‐analysis of determinants of survival following treatment of recurrent hepatocellular carcinoma.
Authors: S. Erridge, P. H. Pucher, S. R. Markar, G. Malietzis, T. Athanasiou, A. Darzi et al.
Notes: No evidence for best treatment
Meta‐analysis of single‐port versus conventional laparoscopic cholecystectomy comparing body image and cosmesis. BJS 2017; 104: 1141-1159.
Authors: R. Haueter, T. Schütz, D. A. Raptis, P.‐A. Clavien, M. Zuber
Notes: Single port superior for cosmesis, body image and pain
Systematic review of the influence of chemotherapy‐associated liver injury on outcome after partial hepatectomy for colorectal liver metastases.
Authors: J. Zhao, K. M. C. van Mierlo, J. Gómez‐Ramírez, H. Kim, C. H. C. Pilgrim, P. Pessaux et al.
Notes: Increased complications in severe SD and steatohepatitis
Authors: R. Ahola, A. Siiki, K. Vasama, M. Vornanen, J. Sand, J. Laukkarinen et al.
Notes: Centralization influences long‐term survival
Systematic review of transarterial embolization for hepatocellular adenomas. BJS 2017; 104: 823-835.
Authors: B. V. van Rosmalen, R. J. S. Coelen, M. Bieze, O. M. van Delden, J. Verheij, C. H. C. Dejong et al.
Notes: Safe alternative to surgery
Meta‐analysis of adjuvant therapy following curative surgery for periampullary adenocarcinoma. BJS 2017; 104: 814-822.
Authors: A. Acharya, S. R. Markar, M. H. Sodergren, G. Malietzis, A. Darzi, T. Athanasiou et al.
Notes: No benefit
Authors: T. Ebata, T. Mizuno, Y. Yokoyama, T. Igami, G. Sugawara, M. Nagino et al.
Notes: irresectability revisited
Survival benefit of liver resection for Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma. BJS 2017; 104: 1045-1052.
Authors: H. Kim, S. W. Ahn, S. K. Hong, K. C. Yoon, H.‐S. Kim, Y. R. Choi et al.
Notes: Selected patients benefit
Accuracy of circulating histones in predicting persistent organ failure and mortality in patients with acute pancreatitis. BJS 2017; 104: 1215-1225.
Authors: T. Liu, W. Huang, P. Szatmary, S. T. Abrams, Y. Alhamdi, Z. Lin et al.
Notes: Potential as early biomarker